Wondering what the changing NHS landscape could mean for patients, services, and clinical pathways? Merck UK & Ireland are excited to announce their new podcast series, NAVIGATE! NAVIGATE aims to educate listeners on the changing UK healthcare landscape and provide NHS stakeholders with recommendations on how they can support the optimal delivery of care in the fast-emerging integrated care landscape. Throughout this series, our Director of Market Access, Amerah Amin, will be joined by several leading experts from across the NHS, to explore different views on how service delivery is evolving in the NHS across a number of conditions, ranging from cancer to neurology care. In doing so, we will consider what exactly emerging Integrated Care Systems (ICSs) could mean for the NHS and the communities and individuals they serve. Stay tuned to catch future episodes of NAVIGATE and be part of this important conversation with Merck!
https://mercknavigate.podbean.com
episode 3: The road to personalised medicine in the NHS – where do we go from here?
Personalised medicine is one of the most exciting areas of healthcare, yet we know it can also be complex. That’s why Merck’s latest episode of NAVIGATE focuses on providing clarity and demystifying what personalised medicine is all about. If you’ve ever been curious about what personalised medicines could mean for patients and the NHS, then be sure to listen in to our latest episode of NAVIGATE!
In this episode, our Market Access director, Amerah Amin, was delighted to talk to Rachel Butler, Consultant Clinical Scientist and Chief Operating Officer at the North Thames Genomic Laboratory Hub and Dr Alastair Greystoke, Honorary Medical Oncologist at Newcastle’s Northern Centre for Cancer Care. Amerah virtually sat down with Rachel and Alastair to discuss what the priorities, challenges and opportunities are to deliver personalised medicine in the NHS.